Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

State of the art — biomarkers in advanced prostate cancer

Nature Reviews Urology volume 23, pages 213–214 (2026)Cite this article

Subjects

Advances in molecular profiling technologies that capture both genotype and phenotype, coupled with an improved understanding of the biological mechanisms underlying prostate cancer progression, set new molecular biomarkers for advancement into the clinic to improve prognostication, therapy selection and disease monitoring for patients with prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091–2102 (2020).

    Article  PubMed  Google Scholar 

  2. Fizazi, K. et al. Rucaparib or physician’s choice in metastatic prostate cancer. N. Engl. J. Med. 388, 719–732 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. van Wilpe, S. et al. Efficacy of anti-PD-(L)1 immunotherapy in patients with DNA mismatch repair-deficient metastatic castration-resistant prostate cancer. Eur. Urol. Oncol. https://doi.org/10.1016/j.euo.2025.04.016 (2025).

    Article  PubMed  Google Scholar 

  4. Swami, U. et al. SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 28, 4917–4925 (2022).

    Article  CAS  PubMed  Google Scholar 

  5. Rathkopf, D. E. et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 36, 76–88 (2025).

    Article  CAS  PubMed  Google Scholar 

  6. Aparicio, A. M. et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin. Cancer Res. 22, 1520–1530 (2016).

    Article  CAS  PubMed  Google Scholar 

  7. Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ku, S. Y. et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355, 78–83 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bakht, M. K. & Beltran, H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat. Rev. Urol. 22, 26–45 (2025).

    Article  CAS  PubMed  Google Scholar 

  10. Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bakht, M. K. et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat. Cancer 4, 699–715 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Boixareu, C., Taha, T., Venkadakrishnan, V. B., de Bono, J. & Beltran, H. Targeting the tumour cell surface in advanced prostate cancer. Nat. Rev. Urol. https://doi.org/10.1038/s41585-025-01014-w (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Helzer, K. T. et al. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann. Oncol. 34, 813–825 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Conteduca, V. et al. Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. Br. J. Cancer 123, 982–987 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 23, 1389–1397 (2022).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, Unit of Medical Oncology and Biomolecular Therapy, University of Foggia, Policlinico Riuniti, Foggia, Italy

    Vincenza Conteduca

  2. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Himisha Beltran

Authors
  1. Vincenza Conteduca
    View author publications

    Search author on:PubMed Google Scholar

  2. Himisha Beltran
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Himisha Beltran.

Ethics declarations

Competing interests

V.C. has served as a consultant and/or advisory board member for Johnson & Johnson, Astellas, Merck, AstraZeneca, Amgen, EISAI, Recordati, Novartis, Ipsen and Bayer and has received speaker honoraria or travel support from Astellas, Johnson & Johnson, Ipsen, Bayer, Gilead, Novartis and Bristol Myers Squibb. H.B. has served as a consultant and/or advisory board member for Janssen, Astellas, Merck, Pfizer, Amgen, Bayer, Daicchi Sankyo, Sanofi, AstraZeneca and Novartis and has received research funding (to institution) from Janssen, Bristol Myers Squibb, Circle Pharma, Daicchi Sankyo and Novartis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Conteduca, V., Beltran, H. State of the art — biomarkers in advanced prostate cancer. Nat Rev Urol 23, 213–214 (2026). https://doi.org/10.1038/s41585-025-01080-0

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-025-01080-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing